Emerging Targeted Therapy for Bladder Cancer

Abstract

For the last decade, biology of urothelial tumorigenesis has been widely explored, helping to better understand the molecular pathways in urothelial carcinoma (UC). Until recently, no targeted therapies have been approved in UC. However, several new molecules have shown promising results in metastatic UC: fibroblast growth factor receptor inhibitors, conjugated antibodies, PARP inhibitors, and antiangiogenics. In this article, the authors review the targeted therapies that are being evaluated in bladder UC.

Keywords: Antiangiogenic; Conjugated antibodies; FGFR inhibitors; PARP inhibitors; Targeted therapies; Urothelial carcinoma.